نتایج جستجو برای: transaminitis

تعداد نتایج: 252  

Journal: :Molecular cancer therapeutics 2010
Teresa Macarulla Andres Cervantes Elena Elez Edith Rodríguez-Braun José Baselga Susana Roselló Gemma Sala Inma Blasco Hadi Danaee Yih Lee Jeffrey Ecsedy Vaishali Shinde Arijit Chakravarty Douglas Bowman Hua Liu Omar Eton Howard Fingert Josep Tabernero

This phase I trial examined the safety, pharmacokinetics, and pharmacodynamics of MLN8054, an oral, selective, small-molecule inhibitor of Aurora A kinase. Patients with advanced solid tumors received increasing doses of MLN8054 in 28-day cycles until dose-limiting toxicity (DLT) was seen in ≥2 of 3-6 patients in a cohort. For the 10-mg and 20-mg cohorts, treatment was administered once daily o...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2017
Neil H Segal Theodore F Logan F Stephen Hodi David McDermott Ignacio Melero Omid Hamid Henrik Schmidt Caroline Robert Vanna Chiarion-Sileni Paolo A Ascierto Michele Maio Walter J Urba Tara C Gangadhar Satyendra Suryawanshi Jaclyn Neely Maria Jure-Kunkel Suba Krishnan Holbrook Kohrt Mario Sznol Ronald Levy

Purpose: Urelumab is an agonist antibody to CD137 with potential application as an immuno-oncology therapeutic. Data were analyzed to assess safety, tolerability, and pharmacodynamic activity of urelumab, including the dose selected for ongoing development in patients with advanced solid tumors and lymphoma.Experimental Design: A total of 346 patients with advanced cancers who had progressed af...

2010
Andres Cervantes Elena Elez Edith Rodríguez-Braun José Baselga Susana Roselló Inma Blasco Hadi Danaee Yih Lee Jeffrey Ecsedy Vaishali Shinde Arijit Chakravarty Hua Liu Omar Eton Howard Fingert Josep Tabernero

nloaded phase I trial examined the safety, pharmacokinetics, and pharmacodynamics of MLN8054, an oral, ve, small-molecule inhibitor of Aurora A kinase. Patients with advanced solid tumors received increasses of MLN8054 in 28-day cycles until dose-limiting toxicity (DLT) was seen in ≥2 of 3-6 patients in a . For the 10-mg and 20-mg cohorts, treatment was administered once daily on days 1 to 5 an...

2007
Laleh Gharahbaghian Douglas P. Brosnan J. Christian Fox Samuel J. Stratton Mark I. Langdorf

This case report describes an unusual presentation of an emergency department (ED) patient with nausea, vomiting, and epigastric pain, who was initially suspected of having viral hepatitis. The patient returned to the ED seven days later with persistent tachycardia and was diagnosed with new onset thyrotoxicosis.

Journal: :The Egyptian Journal of Neurology, Psychiatry and Neurosurgery 2021

Abstract Background NeuroAid II (MLC901) is a promising therapy for stroke patients who present outside of therapeutic window reperfusion therapy. Studies have proven its efficacy in ischemic stroke; however, data drug safety and combination with other medications especially anticoagulants are heterogenous. We report possible case hepatotoxicity induced by anticoagulants. Case presentation an e...

Journal: :Cureus 2023

As many prior case reports have shown, unregulated supplements and alcohol are both known to cause varying degrees of hepatotoxicity. We present a 47-year-old male who presented the hospital with headache abdominal pain after consuming Reishi Mushroom (Ganoderma lingzhi) powder alcohol. The patient was found acute hepatitis significant transaminitis, which managed conservatively N-acetylcystein...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید